A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Zuclopenthixol
Luspatercept
The risk or severity of adverse effects can be increased when Luspatercept is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ascrinvacumab
The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Cixutumumab
The risk or severity of adverse effects can be increased when Cixutumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Inclacumab
The risk or severity of adverse effects can be increased when Inclacumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Etaracizumab
The risk or severity of adverse effects can be increased when Etaracizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ganitumab
The risk or severity of adverse effects can be increased when Ganitumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Zalutumumab
The risk or severity of adverse effects can be increased when Zalutumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Etrolizumab
The risk or severity of adverse effects can be increased when Etrolizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tralokinumab
The risk or severity of adverse effects can be increased when Tralokinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Dupilumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Fasinumab
The risk or severity of adverse effects can be increased when Fasinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Simtuzumab
The risk or severity of adverse effects can be increased when Simtuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Duligotuzumab
The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Gevokizumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sotatercept
The risk or severity of adverse effects can be increased when Sotatercept is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tarextumab
The risk or severity of adverse effects can be increased when Tarextumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Fulranumab
The risk or severity of adverse effects can be increased when Fulranumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Patritumab
The risk or severity of adverse effects can be increased when Patritumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lorvotuzumab mertansine
The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Trastuzumab deruxtecan.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3